Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Osteoporosis: HELP
Articles from Seoul area
Based on 558 articles published since 2008
||||

These are the 558 published articles about Osteoporosis that originated from Seoul area during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Editorial Proper time to initiate antiosteoporotic treatment in rheumatoid arthritis with or without glucocorticoid use. 2014

Lee, Sang-Won. ·Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. ·Korean J Intern Med · Pubmed #25045290.

ABSTRACT: -- No abstract --

2 Review Bisphosphonate therapy for spinal osteoporosis in Hajdu-Cheney syndrome - new data and literature review. 2018

Pittaway, James F H / Harrison, Christopher / Rhee, Yumie / Holder-Espinasse, Muriel / Fryer, Alan E / Cundy, Tim / Drake, William M / Irving, Melita D. ·Department of Endocrinology, St Bartholomew's Hospital, West Smithfield, London, EC1A 7BE, UK. jfhpittaway@doctors.org.uk. · Department of Clinical Genetics, Alder Hey Children's NHS Foundation Trust, E Prescot Rd, Liverpool, L14 5AB, UK. · Department of Internal Medicine, Severance Hospital, Endocrine Research Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea. · Department of Clinical Genetics, Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond, London, SE1 9RT, UK. · Department of Clinical Genetics, Liverpool Women's NHS Foundation Trust, Crown Street, Liverpool, L8 7SS, UK. · Department of Medicine, University of Auckland, 85 Park Rd, Grafton, Auckland, 1023, New Zealand. · Department of Endocrinology, St Bartholomew's Hospital, West Smithfield, London, EC1A 7BE, UK. ·Orphanet J Rare Dis · Pubmed #29618366.

ABSTRACT: BACKGROUND: Hajdu-Cheney syndrome (HCS) (#OMIM 102500) is a rare, autosomal dominant condition that presents in early childhood. It is caused by mutations in the terminal exon of NOTCH2, which encodes the transmembrane NOTCH2 receptor. This pathway is involved in the coupled processes of bone formation and resorption. The skeletal features of HCS include acro-osteolysis of the digits and osteoporosis commonly affecting vertebrae and long bones. Fractures are a prominent feature and are associated with significant morbidity. There is no specific treatment, but with both acro-osteolysis and generalized osteoporosis, it is possible that anti-resorptive treatment might be of benefit. However, to date only a few case reports have evaluated the effectiveness of bisphosphonate treatment. METHODS: We describe the clinical features, treatment regimens and response to bisphosphonate treatment in 7 newly described patients aged 6-39 with HCS, and pooled the data with that from 8 previously published cases (a total of 17 courses of treatment in 15 individuals). RESULTS: The mean lumbar spine bone mineral density (BMD) z-score before treatment was - 2.9 (SD 1.2). In 14 courses of treatment (82%), there was an increase in BMD with bisphosphonate treatment, but the impact (in terms of change in spinal BMD z-score) appeared to be less with advancing age (p = 0.01). There was no evidence that acro-osteolysis was prevented. CONCLUSIONS: Although individual response is variable and age-related, the data support a role for bisphosphonates in preventing or treating spinal osteoporosis in HCS, but bone loss from the lumbar spine may be rapid after cessation.

3 Review Osteoporosis in Rheumatic Diseases: Anti-rheumatic Drugs and the Skeleton. 2018

Dubrovsky, Alanna M / Lim, Mie Jin / Lane, Nancy E. ·Center for Musculoskeletal Health, University of California at Davis Medical Center, Sacramento, CA, 95817, USA. · Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea. · Center for Musculoskeletal Health, University of California at Davis Medical Center, Sacramento, CA, 95817, USA. nelane@ucdavis.edu. · Department of Internal Medicine, University of California at Davis Medical Center, 4625 2nd Avenue, Suite 2000, Sacramento, CA, 95817, USA. nelane@ucdavis.edu. ·Calcif Tissue Int · Pubmed #29470611.

ABSTRACT: Osteoporosis in rheumatic diseases is a very well-known complication. Systemic inflammation results in both generalized and localized bone loss and erosions. Recently, increased knowledge of inflammatory process in rheumatic diseases has resulted in the development of potent inhibitors of the cytokines, the biologic DMARDs. These treatments reduce systemic inflammation and have some effect on the generalized and localized bone loss. Progression of bone erosion was slowed by TNF, IL-6 and IL-1 inhibitors, a JAK inhibitor, a CTLA4 agonist, and rituximab. Effects on bone mineral density varied between the biological DMARDs. Medications that are approved for the treatment of osteoporosis have been evaluated to prevent bone loss in rheumatic disease patients, including denosumab, cathepsin K, bisphosphonates, anti-sclerostin antibodies and parathyroid hormone (hPTH 1-34), and have some efficacy in both the prevention of systemic bone loss and reducing localized bone erosions. This article reviews the effects of biologic DMARDs on bone mass and erosions in patients with rheumatic diseases and trials of anti-osteoporotic medications in animal models and patients with rheumatic diseases.

4 Review Vitamin D deficiency: What does it mean for chronic obstructive pulmonary disease (COPD)? a compherensive review for pulmonologists. 2018

Kokturk, Nurdan / Baha, Ayse / Oh, Yeon-Mok / Young Ju, Jung / Jones, Paul W. ·Department of Pulmonary Medicine, School of Medicine, Gazi University, Ankara, Turkey. · Department of Pulmonary and Critical Care Medicine and Clinical Research Center for Chronic Obstructive Airway Diseases, Asian Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. · Department of Pulmonology, School of Medicine, Clinical Science Center, St George University, London, UK. ·Clin Respir J · Pubmed #27925404.

ABSTRACT: OBJECTIVES: Vitamin D deficiency and Chronic Obstructive Pulmonary Disease (COPD) are both under-recognized health problems, world-wide. Although Vitamin D has long been known for calcemic effects it also has less known noncalcemic effects. Recent data have shown that Vitamin D deficiency is highly prevalent in patients with COPD and correlates with forced expiratory volume in one second (FEV DATA SOURCE: A literature search, using the words "vitamin D" and "COPD", was undertaken in Pubmed database. RESULTS: The noncalcemic effects of vitamin D relating with COPD may be summarised as increasing antimicrobial peptide production, regulation of inflammatory response and airway remodelling. Vitamin D inhibits the production of several proinflammatory cytokines and leads to suppression Th1 and Th17 responses which may be involved in the pathogenesis of COPD. Vitamin D insufficiency may also contribute to chronic respiratory infections and airway colonization so returning vitamin D concentrations to an optimal range in patients with COPD might reduce bacterial load and concomitant exacerbations.Vitamin D is also important for COPD-related comorbodities such as osteoporosis, muscle weakness and cardiovascular diseases. Data about the effect of Vitamin D supplementation on those comorbidities in relation with COPD are been scarce. CONCLUSION: Improving the blood level of Vitamin D into the desired range may have a beneficial effect bones and muscles, but more studies are needed to test to test that hypothesis.

5 Review Nontraumatic Multiple Vertebral Compression Fractures Induced by Primary Hyperparathyroidism: A Case Report and Literature Review. 2017

Choi, Man Kyu / Kim, Sung Min. ·Department of Neurosurgery, Kyung Hee University Hospital, Seoul, South Korea. · Department of Neurosurgery, Kyung Hee University Hospital at Gangdong, Seoul, South Korea. Electronic address: spinekim@khu.ac.kr. ·World Neurosurg · Pubmed #28882718.

ABSTRACT: BACKGROUND: Primary hyperparathyroidism (PHPT) is one of the causes of osteoporosis and is known to increase the fracture risk of bone. However, multiple vertebral compression fracture because of PHPT is extremely rare. CASE DESCRIPTION: A case of acute multiple vertebral compression fracture in a patient with PHPT is described. The fracture occurred suddenly without trauma. The patient had a low T score (-4.4), and serum hypercalcemia and phosphatemia were evident. On examination, serum parathyroid hormone was found to be elevated, and PHPT was diagnosed by neck sonography and technetium-99m methoxyisobutylisonitrile scan. Once the patient was diagnosed with PHPT, we performed subtotal parathyroidectomy and corrective spinal surgery for multiple compression fractures. CONCLUSIONS: When a patient has multiple compression fractures without any trauma history and a very low T score, the presence of other underlying diseases should be investigated.

6 Review A systematic review of diagnostic accuracy of vertebral fracture assessment (VFA) in postmenopausal women and elderly men. 2016

Lee, J-H / Lee, Y K / Oh, S-H / Ahn, J / Lee, Y E / Pyo, J H / Choi, Y Y / Kim, D / Bae, S-C / Sung, Y-K / Kim, D-Y. ·Department of Rheumatology, Inje University Ilsan Paik Hospital, Goyang, Republic of Korea. · National Evidence-based Healthcare Collaborating Agency, Seoul, Republic of Korea. · Department of Biostatistics and Epidemiology, Graduate School of Public Health, Seoul National University, Seoul, Republic of Korea. · WHO Collaborating Centre for Pharmaceutical Science and Regulation, Department of Pharmaceutical Science, Utrecht University, Utrecht, Netherlands. · Department of Nuclear Medicine, Hanyang University Hospital, Seoul, Republic of Korea. · Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea. · Department of Nuclear Medicine, School of Medicine, Kyung Hee University Hospital, Seoul, 130-872, Republic of Korea. deogyoon@daum.net. ·Osteoporos Int · Pubmed #26782682.

ABSTRACT: INTRODUCTION: VFs are recognized as the hallmark of osteoporosis, and a previous VF increases the risk of a future fracture. Therefore, the timely detection of VFs is important for prevention of further fractures. This systematic review examined the diagnostic accuracy of VFA using dual X-ray absorptiometry (DXA) to identify VFs. METHODS: We searched for potentially relevant studies using electronic databases, including Ovid-Medline, Ovid-EMBASE, Cochrane library, and four Korean databases, from their inception to May 2013. We compared the diagnostic accuracy of VFA with that of spinal radiography for detection of VFs by analyzing the sensitivity and specificity using a 2 × 2 contingency table. Subgroup analyses were also performed on studies with a low risk of bias and applicability. RESULTS: Twelve studies were analyzed for the diagnostic accuracy of VFA. The sensitivity and specificity were 0.70-0.93 and 0.95-1.00, respectively, analyzed on a per-vertebra basis, and 0.65-1.00 and 0.74-1.00 on a per-patient basis. The sensitivity and specificity of five studies in subgroups with a low risk of bias in the intervention test were 0.70-0.84 and 0.96-0.99, respectively. In studies with a low risk of bias in the patient selection, those based on a per-vertebra basis in three studies were 0.70-0.93 and 0.96-1.00, respectively. CONCLUSIONS: VFA had moderate sensitivity and high specificity for detecting VF when compared with spinal radiography. However, the present findings are insufficient to assess whether spinal radiography should be replaced by VFA.

7 Review Relationship Between Bariatric Surgery and Bone Mineral Density: a Meta-analysis. 2016

Ko, Byung-Joon / Myung, Seung Kwon / Cho, Kyung-Hwan / Park, Yong Gyu / Kim, Sin Gon / Kim, Do Hoon / Kim, Seon Mee. ·Total Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, 100-742, South Korea. · Molecular Epidemiological Branch, Research Institute, National Cancer Center, Goyang, 410-769, South Korea. · Department of Family Medicine, Hospital, National Cancer Center, Goyang, 410-769, South Korea. · Center for Cancer Prevention and Detection, Hospital, National Cancer Center, Goyang, 410-769, South Korea. · Department of Family Medicine, College of Medicine, Korea University, Seoul, 136-705, South Korea. · Department of Biostatistics, College of Medicine, The Catholic University of Korea, Seoul, 137-701, South Korea. · Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Korea University, Seoul, 136-705, South Korea. · Department of Family Medicine, College of Medicine, Korea University, Seoul, 136-705, South Korea. ksmpdh@korea.ac.kr. ·Obes Surg · Pubmed #26464244.

ABSTRACT: BACKGROUND: A meta-analysis regarding bone loss after bariatric surgery, designed to compare surgical and nonsurgical groups, has not yet been performed. Therefore, we performed a meta-analysis to compare the differences between bariatric surgical groups and nonoperated controls with regard to bone mineral density. METHODS: In March 2015, we performed a review of the literature using PubMed, EMBASE, and the Cochrane Library. The search focused on retrospective and prospective studies, including but not limited to randomized studies published in English. RESULTS: Among 1299 studies that were initially screened, ten met the selection criteria. For all types of bariatric surgery, bone density at the femoral neck was lower in the surgical group than in the nonsurgical control group (mean difference [MD] -0.05 g/cm(2); 95 % confidence interval [CI], -0.07 to -0.02; p = 0.001); no difference in bone density was found between the two groups at the lumbar spine (MD -0.01 g/cm(2); 95 % CI -0.07 to 0.05; p = 0.661). The analysis of Roux-en-Y gastric bypass showed similar results. CONCLUSION: Bone density at the femoral neck decreased after bariatric surgery, compared to that in nonsurgical controls, whereas bone density at the lumbar spine did not show a difference between groups. Further larger scale studies with comparative nonsurgical controls are warranted to overcome the heterogeneity among studies in this analysis and to add evidence of possible bone loss subsequent to bariatric surgical procedures.

8 Review Bone disease in post-transplant patients. 2015

Jeon, Hee Jung / Kim, Hyosang / Yang, Jaeseok. ·aDepartment of Internal Medicine, Hallym University Kangdong Sacred Heart Hospital, Seoul, Republic of Korea bDivision of Nephrology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea cTransplantation Center, Seoul National University Hospital, Seoul, Republic of Korea *Hee Jung Jeon and Hyosang Kim contributed equally to the writing of this article. ·Curr Opin Endocrinol Diabetes Obes · Pubmed #26512770.

ABSTRACT: PURPOSE OF REVIEW: Mineral and bone disorders are common problems in organ transplant recipients. Successful transplantation solves many aspects of abnormal mineral and bone metabolism, but the degree of improvement is frequently incomplete. Posttransplant bone disease can affect long-term outcomes as well as increase the likelihood of fracture. In this article, we reviewed the major posttransplant bone diseases and recent advances in treatment strategies. RECENT FINDINGS: Pretransplant bone disease and immunosuppressants are important risk factors for posttransplant bone disease. Corticosteroid withdrawal may result in minimal or no protection against fractures, with increased risk for acute rejection. Vitamin D analogue and bisphosphonate are frequently used to prevent and treat posttransplant osteoporosis. Posttransplant hyperparathyroidism increases the risk for all-cause mortality and graft loss, but not major cardiovascular events. Cinacalcet was well tolerated and effectively controlled hypercalcemic hyperparathyroidism; however, it did not improve bone mineral density and discontinuation led to parathyroid hormone rebound. Six-month paricalcitol supplementation reduced parathyroid hormone levels and attenuated bone remodeling and mineral loss in case of posttransplant hyperparathyroidism. SUMMARY: Posttransplant bone diseases present in various forms, including osteoporosis, hyperparathyroidism, adynamic bone disease, and osteonecrosis. Prophylactic and therapeutic approaches to both pretransplant and posttransplant periods should be considered.

9 Review Management of osteoporosis in South Korea. 2015

Lee, Young-Kyun / Jang, Sunmee / Ha, Yong-Chan. ·Department of Orthopaedic Surgery, Seoul National University Bundang Hospital, Seoul, Korea. · College of Pharmacy, Gachon University, Incheon, South Korea. ·Crit Rev Eukaryot Gene Expr · Pubmed #25955816.

ABSTRACT: Epidemiologic studies have suggested that South Korea is a country with low risk rates of osteoporosis and osteoporotic fractures. Recently, the Korean Nationwide-Databased Osteoporosis Study (KNOS) performed an overall analysis of osteoporosis using data from the Health Insurance Review and Assessments (HIRA) database. The Korean National Health Insurance Program covers almost 100% of the Korean population, and HIRA reviews all information on medication, operation, and discharge diagnoses according to ICD-10 codes. Therefore, all information about osteoporosis and osteoporotic fractures was obtained from this centralized database. This article reviews the KNOS's efforts to characterize the management of osteoporosis in South Korea.

10 Review Osteoporosis and bone fractures in alcoholic liver disease: a meta-analysis. 2015

Bang, Chang Seok / Shin, In Soo / Lee, Sung Wha / Kim, Jin Bong / Baik, Gwang Ho / Suk, Ki Tae / Yoon, Jai Hoon / Kim, Yeon Soo / Kim, Dong Joon. ·Chang Seok Bang, Sung Wha Lee, Jin Bong Kim, Gwang Ho Baik, Ki Tae Suk, Jai Hoon Yoon, Yeon Soo Kim, Dong Joon Kim, Department of Internal Medicine, Hallym University College of Medicine, Chuncheon 200-704, South Korea. ·World J Gastroenterol · Pubmed #25852292.

ABSTRACT: AIM: To evaluate the association between alcoholic liver disease (ALD) and bone fractures or osteoporosis. METHODS: Non-randomized studies were identified from databases (PubMed, EMBASE, and the Cochrane Library). The search was conducted using Boolean operators and keywords, which included "alcoholic liver diseases", "osteoporosis", or "bone fractures". The prevalence of any fractures or osteoporosis, and bone mineral density (BMD) were extracted and analyzed using risk ratios and standardized mean difference (SMD). A random effects model was applied. RESULTS: In total, 15 studies were identified and analyzed. Overall, ALD demonstrated a RR of 1.944 (95%CI: 1.354-2.791) for the development of bone fractures. However, ALD showed a RR of 0.849 (95%CI: 0.523-1.380) for the development of osteoporosis. BMD was not significantly different between the ALD and control groups, although there was a trend toward lower BMD in patients with ALD (SMD in femur-BMD: -0.172, 95%CI: -0.453-0.110; SMD in spine-BMD: -0.169, 95%CI: -0.476-0.138). Sensitivity analyses showed consistent results. CONCLUSION: Current publications indicate significant associations between bone fractures and ALD, independent of BMD or the presence of osteoporosis.

11 Review Isoflavones: chemistry, analysis, functions and effects on health and cancer. 2014

Ko, Kwang-Pil. ·Department of Preventive Medicine, Gachon University Graduate School of Medicine, Incheon, Korea E-mail : kpko@gachon.ac.kr. ·Asian Pac J Cancer Prev · Pubmed #25227781.

ABSTRACT: Isoflavones are phytoestrogens and natural plant compounds which are similar to 17-β-estradiol in chemical structure. It is known that they can act as estrogen agonists or antagonists, depending on endocrine estrogenic levels, but actions of isoflavones are rather complex due to large number of variables such as chemical structures and mechanisms. Some hypotheses on biological mechanisms have not satisfactorily been confirmed to date and human epidemiological and experimental studies have been relatively limited. Nevertheless, isoflavones and isoflavone rich foods have become a focus on interest due to positive health benefits on many diseases, especially prevention of hormone-related cancers, cardiovascular disease, osteoporosis, and adverse postmenopausal symptoms, and improvement of physiological condition such as maintaining cognitive function. This review provides an overview of chemistry, analytical techniques (focused on human biospecimens), functions including biological mechanisms, and effects of isoflavones, on the basis of the available meta-analysis and review articles and some original articles, on health and cancer.

12 Review Role of miRNAs in bone and their potential as therapeutic targets. 2014

Kim, Kyoung Min / Lim, Sung-Kil. ·Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea. Electronic address: kmkim@snubh.org. · Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: lsk@yuhs.ac. ·Curr Opin Pharmacol · Pubmed #24907412.

ABSTRACT: MicroRNAs (miRNAs) are noncoding, single-stranded RNAs that regulate the expression of target genes by binding their 3'-untranslated region. miRNAs are important regulators of various biological processes, including cellular differentiation, proliferation, apoptosis, and tissue development. Furthermore, aberrant miRNA expression has emerged as an important pathomechanism in various human diseases, including osteoporosis. Thus, the therapeutic potential of miRNA has attracted great interest recently. Here, we focused on the roles of miRNAs in bone homeostasis and the potential of miRNAs as therapeutic targets.

13 Review The relationship between osteoarthritis and osteoporosis. 2014

Im, Gun-Il / Kim, Min-Kyu. ·Department of Orthopaedics, Dongguk University Ilsan Hospital, Goyang, 410-773, Republic of Korea, gunil@duih.org. ·J Bone Miner Metab · Pubmed #24196872.

ABSTRACT: The relationship between osteoarthritis (OA) and osteoporosis (OP), the two most common skeletal disorders related to aging, is controversial. Previous studies suggest that OA is inversely related to OP when studied cross-sectionally and systematically. However, there are differences in the results depending on the parameter used to define OA. The purpose of this review is to analyze and summarize the literature, and derive possible answers to three key questions along with a brief introduction on underlying mechanisms: (1) Is OA correlated to a high bone mineral density (BMD)? (2) Does OA influence the progression of OP or osteoporotic fractures? (3) Does high BMD affect the incidence and progression of OA? A review of the literature suggests that OA is inversely related to OP in general when studied cross-sectionally and systematically. However, when analyzed in individual bones, the BMD of the appendicular skeleton in OA-affected joints may decrease, particularly in the upper extremities. On whether OA influences bone loss or osteoporotic fractures, differences are observed according to the affected joints. The risk for osteoporotic fracture does not seem to decrease despite a high BMD in patients with OA, probably due to postural instability and muscle strength. Low BMD at the lumbar spine is associated with a lower incidence of knee OA although it does not arrest the progression of knee OA.

14 Review Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. 2012

Lee, Jehoon / Vasikaran, Samuel. ·Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. ·Ann Lab Med · Pubmed #22389876.

ABSTRACT: Osteoporosis is a major health problem worldwide, and is projected to increase exponentially due to the aging of the population. The absolute fracture risk in individual subjects is calculated by the use of algorithms which include bone mineral density (BMD), age, gender, history of prior fracture and other risk factors. This review describes the laboratory investigations into osteoporosis which include serum calcium, phosphate, creatinine, alkaline phosphatase and 25-hydroxyvitamin D and, additionally in men, testosterone. Parathyroid hormone (PTH) is measured in patients with abnormal serum calcium to determine its cause. Other laboratory investigations such as thyroid function testing, screening for multiple myeloma, and screening for Cushing's syndrome, are performed if indicated. Measurement of bone turnover markers (BTMs) is currently not included in algorithms for fracture risk calculations due to the lack of data. However, BTMs may be useful for monitoring osteoporosis treatment. Further studies of the reference BTMs serum carboxy terminal telopeptide of collagen type I (s-CTX) and serum procollagen type I N-terminal propeptide (s-PINP) in fracture risk prediction and in monitoring various treatments for osteoporosis may help expedite their inclusion in routine clinical practice.

15 Review Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials. 2011

Lee, Young Ho / Song, Gwan Gyu. ·Division of Rheumatology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. lyhcgh@korea.ac.kr ·Korean J Intern Med · Pubmed #22016595.

ABSTRACT: BACKGROUND/AIMS: The aim of this study was to assess the efficacy and safety of monthly oral 150 mg ibandronate in women with postmenopausal osteoporosis (PMO). METHODS: A systematic review and meta-analysis were performed to determine treatment efficacy and safety outcomes between monthly oral 150 mg ibandronate and weekly 70 mg alendronate, daily 2.5 mg ibandronate, and a placebo. RESULTS: Eight randomized controlled trials were included in this systematic review and meta-analysis. Once-monthly 150 mg ibandronate therapy was clinically comparable to weekly 70 mg alendronate, showing increased bone mineral density (BMD) in both the lumbar spine and total hip. Pooled data from two cross-over trials showed that significantly more women with PMO preferred once-monthly ibandronate therapy to once-weekly alendronate therapy (relative risk [RR], 2.422; 95% confidence interval [CI], 2.111 to 2.825; p < 1 × 10(-8)) and found the monthly ibandronate regimen more convenient than the weekly alendronate regimen (RR, 3.096; 95% CI, 2.622 to 3.622; p < 1 × 10(-8)). Monthly 150 mg ibandronate therapy resulted in a significantly higher change in BMD of the lumbar spine than with the placebo. A once monthly 150 mg regimen produced greater increases in lumbar spine, total hip, femoral neck, and trochanter BMD than daily treatment, with a similar incidence of adverse events between the groups. CONCLUSIONS: Once monthly 150 mg ibandronate therapy was clinically comparable to weekly 70 mg alendronate, and patients strongly preferred the convenience of monthly ibandronate over weekly alendronate. Monthly 150 mg ibandronate was superior to, and as well tolerated as, the daily treatment.

16 Review [Nutrition in inflammatory bowel disease]. 2008

Lee, Kang Moon. ·Department of Internal Medicine, The Catholic University of Korea College of Medicine, Suwon, Korea. drmaloman@catholic.ac.kr ·Korean J Gastroenterol · Pubmed #19077484.

ABSTRACT: Nutrition, as a definite environmental factor, has been implicated in the pathogenesis of inflammatory bowel disease (IBD). Although low-fiber, high-sugar, and high-animal fat diets have been proposed as a risk factor, the role of nutrition in IBD still needs more conclusive evidence. Nutritional deficiency is a common problem in IBD patients. The goals of nutritional intervention are the prevention and correction of malnutrition, the prevention of osteoporosis, and the promotion of optimal growth and development in childhood. Enteral nutrition is effective in induction and maintenance of the clinical remission in adults and promoting growth in children with Crohn's disease. The n-3 polyunsaturated fatty acids contained in fish oil may provide short-term benefit to patients with IBD.

17 Review Hormone-dependent aging problems in women. 2008

Jung, Byung Hwa / Jeon, Myung Jae / Bai, Sang Wook. ·Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology, Seoul, Korea. ·Yonsei Med J · Pubmed #18581581.

ABSTRACT: One of the major social issues nowadays is the aging society. Korea is already an aging society, and 63 cities and districts are ultra-aged societies where the rate of people older than 65 yr exceeds 20%. Among them, more than 67% are women. These statistics reveal the importance of healthcare for older women. Disease and disability of older women are very closely related to the loss of female sex hormones after menopause. Major hormone-dependent aging problems in women such as osteoporosis, Alzheimer's disease (AD), urinary incontinence, and coronary atherosclerosis were surveyed in this review, and the key role of hormones in those diseases and hormone replacement therapy (HRT) were summarized. We expect that this review would provide some understanding of factors that must be considered to give optimal care to older women for healthy lives.

18 Clinical Trial ACTN3 Gene and Susceptibility to Sarcopenia and Osteoporotic Status in Older Korean Adults. 2017

Cho, Jinkyung / Lee, Inhwan / Kang, Hyunsik. ·College of Sport Science, Sungkyunkwan University, Suwon, Republic of Korea. ·Biomed Res Int · Pubmed #28626757.

ABSTRACT: BACKGROUND: Little information is available about molecular markers for sarcopenia and osteoporosis in Asian populations. OBJECTIVE: This study investigated the association of the METHODS: Older Korean 62 men and 270 women (mean age 73.7 ± 6.6 years) participated in this study. Body mass index, percent body fatness, appendicular skeletal muscle mass, and bone mineral density of the lumbar spine, femur, and total body were analyzed with dual-energy X-ray absorptiometry. RESULTS: Determination of odds ratios (ORs) and 95% confidence intervals (CIs) using binary logistic regression analyses showed that XX homozygotes were at a significantly higher risk of sarcopenia (OR = 2.056, 95%  CI = 1.024-4.127, CONCLUSION: Our findings suggest that the

19 Clinical Trial Vitamin D Repletion in Korean Postmenopausal Women with Osteoporosis. 2016

Chung, Yoon Sok / Chung, Dong Jin / Kang, Moo Il / Kim, In Ju / Koh, Jung Min / Min, Yong Ki / Oh, Han Jin / Park, Il Hyung / Lee, Yil Seob / Kravitz, Barbara / Waterhouse, Brian / Fitzpatrick, Lorraine A / Nino, Antonio. ·Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea. · Division of Endocrinology and Metabolism, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea. · Department of Endocrinology and Metabolism, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea. · Department of Endocrinology and Metabolism, Pusan National University Hospital, Busan, Korea. · Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. · Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. · Department of Family Medicine, Cheil General Hospital, College of Medicine, Kwandong University, Seoul, Korea. · Department of Orthopedic Surgery, Kyungpook National University Hospital, Daegu, Korea. · GlaxoSmithKline, Seoul, Korea, Korea. · GlaxoSmithKline, Collegeville, PA, USA. barbara.g.kravitz@gsk.com. · GlaxoSmithKline, Collegeville, PA, USA. ·Yonsei Med J · Pubmed #27189286.

ABSTRACT: PURPOSE: Up to 71% of South Korean postmenopausal women have vitamin D deficiency {serum 25-hydroxyvitamin D [25(OH) D] level <50 nmol/L}. Data on vitamin D supplementation was collected during the screening phase of an efficacy/safety study of denosumab in Korean postmenopausal women with osteoporosis. This report describes the effect of vitamin D supplementation on repletion to 25(OH)D levels ≥50 nmol/L in Korean postmenopausal women with osteoporosis. MATERIALS AND METHODS: Vitamin D levels of Korean postmenopausal women (60-90 years old) were measured by extracting 25(OH)D₂ and 25(OH)D₃ from serum samples via protein precipitation and using liquid chromatography with tandem mass spectrometry detection. Calibration curves were constructed from the mass chromatograms to obtain total vitamin D levels. Subjects with serum 25(OH)D levels <50 nmol/L were supplemented with 1000 IU of vitamin D tablets during the 2.5-month-long screening period. Dose, frequency, and duration were determined by the investigator. If repletion was achieved (≥50 nmol/L) on retest, subjects were eligible to be rescreened for study entry. RESULTS: Of 371 subjects screened, 191 (52%) required vitamin D supplementation, and 88% (168 of 191) were successfully repleted. More than half of the subjects (58%) who were successfully repleted received doses of 2000 IU daily. The mean time to successful repletion was 31 days (standard deviation 8.4 days; range 11-48 days). CONCLUSION: Supplementation with daily median doses of 2000 IU vitamin D successfully repleted 88% of Korean postmenopausal women with osteoporosis within 48 days to a serum vitamin D level of 50 nmol/L.

20 Clinical Trial Assessment of Denosumab in Korean Postmenopausal Women with Osteoporosis: Randomized, Double-Blind, Placebo-Controlled Trial with Open-Label Extension. 2016

Koh, Jung Min / Chung, Dong Jin / Chung, Yoon Sok / Kang, Moo Il / Kim, In Ju / Min, Yong Ki / Oh, Han Jin / Park, Il Hyung / Lee, Yil Seob / Kravitz, Barbara / Waterhouse, Brian / Nino, Antonio / Fitzpatrick, Lorraine A. ·Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. · Division of Endocrinology and Metabolism, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea. · Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea. · Department of Endocrinology and Metabolism, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea. · Department of Endocrinology and Metabolism, Pusan National University Hospital, Busan, Korea. · Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. · Department of Family Medicine, Cheil General Hospital, College of Medicine, Kwandong University, Seoul, Korea. · Department of Orthopedic Surgery, Kyungpook National University Hospital, Daegu, Korea. · GlaxoSmithKline, Seoul, Korea. · GlaxoSmithKline, Collegeville, PA, USA. barbara.g.kravitz@gsk.com. · GlaxoSmithKline, Collegeville, PA, USA. ·Yonsei Med J · Pubmed #27189284.

ABSTRACT: PURPOSE: The efficacy and safety of denosumab was compared with placebo in Korean postmenopausal women with osteoporosis in this phase III study. MATERIALS AND METHODS: Women aged 60 to 90 years with a T-score of <-2.5 and ≥-4.0 at the lumbar spine or total hip were randomized to a single 60 mg subcutaneous dose of denosumab or placebo for the 6-month double-blind phase. Eligible subjects entered the 6-month open-label extension phase and received a single dose of denosumab 60 mg. RESULTS: Baseline demographics were similar in the 62 denosumab- and 64 placebo-treated subjects who completed the double-blind phase. Treatment favored denosumab over placebo for the primary endpoint {mean percent change from baseline in lumbar spine bone mineral density (BMD) at Month 6 [3.2% (95% confidence interval 2.1%, 4.4%; p<0.0001)]}; and secondary endpoints (mean percent change from baseline in lumbar spine BMD at Month 1, total hip, femoral neck, and trochanter BMD at Months 1 and 6, and median percent change from baseline in bone turnover markers at Months 1, 3, and 6). Endpoint improvements were sustained over 12 months in the open-label extension (n=119). There were no new or unexpected safety signals. CONCLUSION: Denosumab was well tolerated and effective in increasing BMD and decreasing bone turnover markers over a 12-month period in Korean postmenopausal women. The findings of this study demonstrate that denosumab has beneficial effects on the measures of osteoporosis in Korean postmenopausal women.

21 Clinical Trial Z-score discordance and contributing factors in healthy premenopausal women with low bone mineral density: the Korean National Health and Nutrition Examination Survey 2008-9. 2016

Park, Kyeong Hye / Lim, Jung Soo / Kim, Kyoung Min / Rhee, Yumie / Lim, Sung-Kil. ·Division of Endocrinology and Metabolism, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Gyeonggi, South Korea. · Yonsei University Graduate School of Medicine, Seoul, South Korea. · Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Gangwon, South Korea. · Department of Internal Medicine, Seoul National University Bundang Hospital, Sungnam, Gyeonggi, South Korea. · Division of Endocrinology, Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, South Korea. · Division of Endocrinology, Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, South Korea. lsk@yuhs.ac. ·J Bone Miner Metab · Pubmed #26445825.

ABSTRACT: The premenopausal period is important for bone health and prevention of future fractures, but measuring bone mineral density (BMD) at only one site may not be sufficient to determine therapeutic strategies for low BMD in premenopausal women due to the presence of Z-score discordance. In this study, we investigated Z-score discordance in addition to contributing factors of idiopathic low BMD in healthy premenopausal Korean women. We studied 3003 premenopausal women aged 18-50 years, without secondary causes for low BMD and history of fragility fracture, who had participated in the Fourth Korean National Health and Nutrition Examination Surveys (2008-2009). Low body mass index (BMI), low vitamin D level, and low body muscle mass were associated with low BMD even in premenopausal women. Risk factors differed depending on the anatomic site. Low BMI and low vitamin D level were risk factors for low femoral neck BMD (FN-BMD), but not for low lumbar spine BMD (LS-BMD). Only total muscle mass had a slight effect on low LS-BMD. Z-score discordance was much higher than expected, in 75 and 73.8 % of the low LS-BMD and low FN-BMD groups, respectively. Our findings suggest the need to consider BMD discordance in premenopausal women and also to provide information on correctable factors affecting low BMD in younger populations. Long-term follow-up is needed to evaluate the possible effect of Z-score discordance on the prognosis of osteoporosis and subsequent fracture risk.

22 Clinical Trial Different reference BMDs affect the prevalence of osteoporosis. 2016

Jung, Ki Jin / Chung, Chin Youb / Park, Moon Seok / Kwon, Soon-Sun / Moon, Sang Young / Lee, In Hyeok / Kim, Ka Hyun / Lee, Kyoung Min. ·Department of Orthopaedic Surgery, Soonchunhyang University Cheonan Hospital, 23-20 Byeongmyeong-Dong, Dongnam-Gu, Cheonan, Chungcheongnam-Do, 330-721, Korea. · Department of Orthopaedic Surgery, Seoul National University Bundang Hospital, 300 Gumi-Dong, Bundang-Gu, Seongnam, Kyeonggi-do, 463-707, Korea. · Department of Biomedical Research Institute, Seoul National University Bundang Hospital, 300 Gumi-Dong, Bundang-Gu, Seongnam, Kyeonggi-do, Korea. · Department of Orthopaedic Surgery, Hallym University Chuncheon Sacred Heart Hospital, 77 Sakju-Ro, Chuncheon-Si, Gangwon-Do, 200-704, Korea. · Department of Orthopaedic Surgery, Sungkyunkwan University Samsung Changwon Hospital, 158, Palyoung-Ro, MasanHoiwon-Gu, Changwon, Gyeongnam-Do, 630-522, Korea. · Department of Orthopaedic Surgery, Seoul National University Bundang Hospital, 300 Gumi-Dong, Bundang-Gu, Seongnam, Kyeonggi-do, 463-707, Korea. oasis100@empal.com. ·J Bone Miner Metab · Pubmed #26058492.

ABSTRACT: The T score represents the degree of deviation from the peak bone mineral density (BMD) (reference standard) in a population. Little has been investigated concerning the age at which the BMD reaches the peak value and how we should define the reference standard BMD in terms of age ranges. BMDs of 9,800 participants were analyzed from the Korean National Health and Nutrition Examination Survey database. Five reference standards were defined: (1) the reference standard of Japanese young adults provided by the dual-energy X-ray absorptiometry machine manufacturer, (2) peak BMD of the Korean population evaluated by statistical analysis (second-order polynomial regression models), (3) BMD of subjects aged 20-29 years, (4) BMD of subjects aged 20-39 years, and (5) BMD of subjects aged 30-39 years. T-scores from the five reference standards were calculated, and the prevalence of osteoporosis was evaluated and compared for males and females separately. The peak BMD in the polynomial regression model was achieved at 26 years in males and 36 years in females in the total hip, at 20 years in males and 27 years in females in the femoral neck, and at 20 years in males and 30 years in females in the lumbar spine. The prevalence of osteoporosis over the age of 50 years showed significant variation of up to two fold depending on the reference standards adopted. The age at which peak BMD was achieved was variable according to the gender and body sites. A consistent definition of peak BMD needs to be established in terms of age ranges because this could affect the prevalence of osteoporosis and healthcare policies.

23 Clinical Trial Assessment of osteoporosis using pelvic diagnostic computed tomography. 2016

Kim, Yee-Suk / Lee, Seunghun / Sung, Yoon-Kyoung / Lee, Bong-Gun. ·Department of Orthopedic Surgery, College of Medicine, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul, South Korea, 133-791. estone96@gmail.com. · Department of Radiology, College of Medicine, Hanyang University, Seoul, South Korea. · Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea. · Department of Orthopedic Surgery, College of Medicine, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul, South Korea, 133-791. ·J Bone Miner Metab · Pubmed #26056023.

ABSTRACT: The purpose of the present study is to determine if a correlation exists between bone mineral density (BMD) obtained from dual energy X-ray absorptiometry (DXA) and Hounsfield unit (HU) from pelvic diagnostic computed tomography (dCT), and to evaluate whether HU could be used to identify osteoporosis. Seventy-nine patients were included in this study. HU values were measured in three different sections: the head-neck junction of the femur, the middle portion of the femoral neck, and the intertrochanter of the femur (IT). In each sectional image, HU values were measured at two regions of interest: cortical and cancellous bone (HU_t) and cancellous bone. The correlation between BMD and HU_t of IT was significant (r = 0.839, p < 0.01). In IT, the area under the curve value of HU_t was 0.875 (0.796-0.955). We found that a HU_t of IT <170 can be regarded as indicating osteoporosis: its positive predictive value is 96.9 %. A HU_t of IT >210 can be regarded as indicating an absence of osteoporosis: its negative predictive value is 84.6 %. In conclusion, we found that a significant correlation between HU of pelvic dCT and BMD of DXA, and HU potentially provided an alternative method for determining regional BMD. Therefore, pelvic dCT could possibly be a supplementary method for initial diagnosis of osteoporosis and for initiation of treatment.

24 Clinical Trial Gender- and age-group-specific associations between physical performance and bone mineral density, falls, and osteoporotic fractures in Koreans: the Chungju Metabolic Disease Cohort study. 2016

Lim, Yejee / Kim, Kyunghee / Ko, Sun-Hee / Cho, Kwanhoon / Jang, Eun-Hee / Lee, Seung-Hwan / Lim, Dong Jun / Baek, Ki Hyun / Ha, Hee-Sung / Park, Mi Sun / Yim, Hyeon-Woo / Lee, Won-Chul / Yoon, Kun-Ho / Son, Ho Young / Oh, Ki Won / Kang, Moo-Il. ·Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, 222 Banpo-daero Seocho-gu, Seoul, 137-701, South Korea. · Department of Preventive Medicine, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 137-701, South Korea. · Clinical Research Coordinating Center, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 137-701, South Korea. · Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul, 110-746, South Korea. · Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, 222 Banpo-daero Seocho-gu, Seoul, 137-701, South Korea. mikang@catholic.ac.kr. ·J Bone Miner Metab · Pubmed #26056017.

ABSTRACT: Several factors increase the risk of fragility fracture, including low bone mineral density, falls, and poor physical performance. The associations among these factors have been investigated; however, most of the subjects of previous studies were either elderly men or elderly women, and the associations were controversial. The aim of this study was to evaluate the associations between physical performance and bone mineral density, and the history of falls and fractures, stratified by gender and age group. We analyzed 5368 subjects who were aged 50 years or older, including 1288 younger men (younger than 70 years), 1615 younger women (younger than 70 years), 1087 older men (70 years or older), and 1378 older women (70 years or older). We used the one-leg standing time (OLST) for assessing static balance and the timed up-and-go test (TUGT) for assessing dynamic balance. The subjects in the worst performance quartile for the OLST were more likely to have osteoporosis than those in the best performance quartile. Additionally, women who had experienced a fracture during the past 2 years were 1.68 times more likely to be in the worst performance quartile for the OLST than women without a previous fracture. Although the TUGT time was not associated with either the incidence of osteoporosis or the fracture history, the odds ratios for falling were 1.51 and 1.28 as the TUGT time increased by one standard deviation in younger men and younger women, respectively. The findings of the present study show that the OLST was associated with the incidence of osteoporosis and previous fracture and that the TUGT time was associated with the incidence of falling.

25 Clinical Trial Improved dosage form of the combined alendronate and calcitriol (Maxmarvil®) on the absorption of alendronate in Korean postmenopausal women. 2013

Chung, Yoon-Sok / Choi, Yong Jun / Kim, So Hee. ·Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea. ·Arch Pharm Res · Pubmed #23681426.

ABSTRACT: Alendronate is one of the most potent anti-osteoporotic agents for postmenopausal osteoporosis. However, high doses of alendronate cause esophageal irritation, myalgia, gastrointestinal discomfort and decrease of serum calcium level. Recently, Maxmarvil® was developed as an enteric-coated tablet containing alendronate (5 mg) and calcitriol (0.5 μg) to minimize these side effects of alendronate. In the present study, we evaluated the pharmacokinetic profile and examined the incidence of unfavorable effects after oral administration of Maxmarvil® in Korean healthy postmenopausal women without a previous history of fracture. In the in vitro dissolution test, alendronate was not released from Maxmarvil® in pH 1.2 phosphate buffer solution but released in pH 6.0 and 6.8 phosphate buffer solutions and completely dissolved in 30 min. After oral administration of Maxmarvil®, three out of 18 (16.7%) women showed mild adverse effects; two myalgia and one upper gastrointestinal discomfort without heartburn. Most of these complaints disappeared during the study without additional treatment. The peak (Umax) and the average (Uave) urinary excretion rate of alendronate and the time to reach Umax (Tmax) were 2.94 μg/h, 0.901 μg/h and 6.77 h, respectively. The total cumulative urinary excretion of alendronate (Ae₀₋₂₄ h) was 21.6 μg (0.432% of oral alendornate), which was similar to the reported values. Taken together, enteric-coated Maxmarvil® is less harmful for the esophagus and gastrointestinal mucosa, shows the same pharmacokinetic profile to conventional alendronate (70 mg) and improves the tolerability of medication in clinical practice.

Next